These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16177669)

  • 1. New aldosteron receptor inhibitors in heart failure.
    Mandolini C; Vacca K; Borgia MC
    Minerva Cardioangiol; 2005 Aug; 53(4):241-8. PubMed ID: 16177669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exciting new drugs on the horizon - eplerenone, a selective aldosterone receptor antagonist (SARA).
    Coats AJ
    Int J Cardiol; 2001 Aug; 80(1):1-4. PubMed ID: 11532539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
    Iraqi W; Rossignol P; Angioi M; Fay R; Nuée J; Ketelslegers JM; Vincent J; Pitt B; Zannad F
    Circulation; 2009 May; 119(18):2471-9. PubMed ID: 19398668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking aldosterone in heart failure.
    Shafiq MM; Miller AB
    Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):379-85. PubMed ID: 19661156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
    Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review article: eplerenone: an underused medication?
    Abuannadi M; O'Keefe JH
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):318-25. PubMed ID: 20876342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eplerenone in the treatment of chronic heart failure.
    Krum H; Liew D
    Expert Rev Cardiovasc Ther; 2004 May; 2(3):315-20. PubMed ID: 15151479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J; Fraccarollo D
    Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
    Barnes BJ; Howard PA
    Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do diuretics and aldosterone receptor antagonists improve ventricular remodeling?
    Pitt B
    J Card Fail; 2002 Dec; 8(6 Suppl):S491-3. PubMed ID: 12555163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldosterone antagonists in hypertension and heart failure.
    Mantero F; Lucarelli G
    Ann Endocrinol (Paris); 2000 Feb; 61(1):52-60. PubMed ID: 10790593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure.
    Iqbal J; Parviz Y; Pitt B; Newell-Price J; Al-Mohammad A; Zannad F
    Eur J Heart Fail; 2014 Feb; 16(2):143-50. PubMed ID: 24464876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective aldosterone blockade with eplerenone in patients with congestive heart failure.
    Salam AM
    Expert Opin Investig Drugs; 2003 Aug; 12(8):1423-7. PubMed ID: 12882627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug insight: aldosterone-receptor antagonists in heart failure--the journey continues.
    Kalidindi SR; Tang WH; Francis GS
    Nat Clin Pract Cardiovasc Med; 2007 Jul; 4(7):368-78. PubMed ID: 17589427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection.
    Sato A; Saruta T; Funder JW
    Hypertens Res; 2006 Apr; 29(4):211-6. PubMed ID: 16778327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
    Butler J; Ezekowitz JA; Collins SP; Givertz MM; Teerlink JR; Walsh MN; Albert NM; Westlake Canary CA; Carson PE; Colvin-Adams M; Fang JC; Hernandez AF; Hershberger RE; Katz SD; Rogers JG; Spertus JA; Stevenson WG; Sweitzer NK; Tang WH; Stough WG; Starling RC
    J Card Fail; 2012 Apr; 18(4):265-81. PubMed ID: 22464767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldosterone antagonists: a new treatment option for patients with post-myocardial infarction heart failure.
    Ajani AE; Marwick TH; Krum H
    Cardiovasc Revasc Med; 2006; 7(4):234-6. PubMed ID: 17174870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of aldosterone-antagonists in the treatment of congestive heart failure].
    Fügedi K
    Orv Hetil; 2005 Apr; 146(14):645-8. PubMed ID: 15889538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.